SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001010192-13-000101
Filing Date
2013-12-03
Accepted
2013-12-03 16:13:47
Documents
2

Document Format Files

Seq Description Document Type Size
1 TRANSCEPT SCHEDULE 13D/A 12-3-13 sch13da.htm SC 13D/A 36729
2 EXHIBIT 7.07 TO 13D/A 12-3-13 exh707.htm EX-7.07 11209
  Complete submission text file 0001010192-13-000101.txt   49571
Mailing Address 1003 W. CUTTING BLVD SUITE 110 POINT RICHMOND CA 94804
Business Address 1003 W. CUTTING BLVD SUITE 110 POINT RICHMOND CA 94804 (510) 215-3500
Transcept Pharmaceuticals Inc (Subject) CIK: 0001178711 (see all company filings)

IRS No.: 330960223 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-81821 | Film No.: 131254561
SIC: 2834 Pharmaceutical Preparations

Mailing Address 2 WISCONSIN CIR SUITE 660 CHEVY CHASE MD 20815
Business Address 2 WISCONSIN CIR SUITE 660 CHEVY CHASE MD 20815 301-656-8500
Roumell Asset Management, LLC (Filed by) CIK: 0001331693 (see all company filings)

IRS No.: 522145132 | State of Incorp.: MD | Fiscal Year End: 1231
Type: SC 13D/A